Physician profile
Essam Malaty
NPI 1508887191
$4,682.92
in general payments reported to CMS, 2019-2025
42 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $1,314 · 2021: $1,049 · 2022: $382 · 2023: $155 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.74 |
| Education | $168.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $747.56 | 2019-2025 | Opdivo |
| Amgen INC. | $580.91 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $404.59 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $265.08 | 2019-2025 | Keytruda, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $236.95 | 2019-2025 | |
| Celgene Corporation | $195.98 | 2019-2025 | Reblozyl |
| Pfizer INC. | $166.89 | 2019-2025 | |
| Abbvie INC. | $160.86 | 2022-2025 | |
| Incyte Corporation | $159.17 | 2019-2025 | Jakafi |
| Astellas Pharma US INC | $153.59 | 2020-2021 | |
| Janssen Biotech, INC. | $132.08 | 2019-2025 | Darzalex, Tecvayli |
| Pharmacyclics LLC, An Abbvie Company | $130.20 | 2023 | Imbruvica |
| Daiichi Sankyo INC. | $99.52 | 2019-2025 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $93.92 | 2021-2022 | |
| Eisai INC. | $91.80 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Essam Malaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.